# Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

> **NCT01473524** · PHASE3 · COMPLETED · sponsor: **Intercept Pharmaceuticals** · enrollment: 217 (actual)

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** Obeticholic Acid (OCA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01473524
- **Lead sponsor:** Intercept Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-12
- **Final completion:** 2018-12-17
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473524, "Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01473524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*